CaaMTech Teams Up With University of Wyoming to Study Psychedelics as Treatments for Addiction Post published:November 16, 2021 Post category:Press Release
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development Post published:September 8, 2021 Post category:Press Release
Patent Combining Psychedelics with Cannabinoids Allowed by USPTO Post published:February 10, 2021 Post category:Press Release
Andrew Chadeayne, Founder and CEO of CaaMTech Post published:December 10, 2020 Post category:Interview
CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth Post published:December 9, 2020 Post category:Press Release
CaaMTech Collaborates With the Leibniz Institute for Natural Product Research to Investigate Psychedelic Mushrooms Post published:December 1, 2020 Post category:Press Release
CaaMTech Researchers Synthesize and Structurally Characterize Deprocin Hydrochloride Post published:November 30, 2020 Post category:Press Release
CaaMTech Synthesizes Novel Tryptamine Prophoria™, Amphoria™ Post published:July 7, 2020 Post category:Press Release